爱尔眼科(kē)医院集团是具有(yǒu)中國(guó)及全球范围医院规模和优质医疗能(néng)力的眼科(kē)医疗集团，服務(wù)覆盖亚洲、欧洲和北美洲，在中國(guó)内地、欧洲、东南亚拥有(yǒu)3家上市公司(中國(guó)A股：爱尔眼科(kē)，300015;西班牙：CBAV;新(xīn)加坡：40T)。目前在全球范围内开设眼科(kē)医院及中心达720家，其中中國(guó)内地611家、中國(guó)香港7家、美國(guó)1家、欧洲89家、东南亚12家。2020年，中國(guó)内地年门诊量超1000万人次，手术量超100万台，医疗服務(wù)网络覆盖全球近30亿人口。
AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.
爱尔眼科(kē)始终坚持以國(guó)内发展為(wèi)主線(xiàn)，國(guó)内國(guó)际双線(xiàn)并举，共同进步。在发展的过程中，致力于引进和吸收國(guó)际同步的眼科(kē)技术与医疗管理(lǐ)理(lǐ)念，以专业化、规模化、科(kē)學(xué)化為(wèi)发展战略，推动中國(guó)眼科(kē)医疗事业的发展。通过不断实践，在充分(fēn)吸收國(guó)际优质的医疗管理(lǐ)经验的基础上，成功探索出一套适应中國(guó)國(guó)情和市场环境的眼科(kē)医院连锁经营管理(lǐ)模式——“分(fēn)级连锁”，充分(fēn)发挥人才、技术和管理(lǐ)等方面的优势，提升诊疗质量、完善医疗服務(wù)、优化医患沟通。
Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.
AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.
科(kē)研创新(xīn)、人才培养是長(cháng)遠(yuǎn)发展的基石，爱尔眼科(kē)不断加大科(kē)研投入，大力支持开展前沿性、原创性的眼科(kē)學(xué)术研究，全力推进全球化平台上的眼健康生态圈战略。自2013年爱尔眼科(kē)与中南大學(xué)联合成立中南大學(xué)爱尔眼科(kē)學(xué)院，正式开启校企合作的创新(xīn)探索以来，陆续推动了与湖(hú)北科(kē)技學(xué)院、武汉大學(xué)、暨南大學(xué)、安徽医科(kē)大學(xué)、天津大學(xué)、四川大學(xué)等知名高校的战略合作，充分(fēn)发挥企业和高校的独特优势，在医院共建、人才培养、师资队伍建设、教學(xué)科(kē)研等领域展开深入合作，联手共建眼科(kē)医教研平台，合力打造“名校+名企”典范，為(wèi)社会培养更多(duō)优秀的眼科(kē)医學(xué)人才，真正地為(wèi)中國(guó)眼科(kē)學(xué)和视觉科(kē)學(xué)的创新(xīn)发展贡献智慧与力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.
在此基础上，爱尔眼科(kē)持续打造立體(tǐ)化科(kē)研平台，截止目前已在全國(guó)范围内构建起“八所、二站、二基地、三中心”的创新(xīn)型科(kē)教研一體(tǐ)化平台。“八所”：爱尔眼科(kē)研究所、爱尔眼视光研究所、爱尔角膜病研究所、爱尔屈光研究所、爱尔视网膜研究所、爱尔青光眼研究所、爱尔白内障与人工晶状體(tǐ)研究所、武汉爱尔眼科(kē)研究所。获批设立“二站”：國(guó)家博士后科(kē)研工作站、湖(hú)南省院士专家工作站；“二基地”：湖(hú)南省眼视光國(guó)际科(kē)技合作基地、湖(hú)南省“海智计划”工作基地；“三中心”：湖(hú)南省眼视光工程技术研究中心、湖(hú)南省眼表疾病临床医學(xué)研究中心、湖(hú)南省企业技术中心；联合共建“爱尔眼科(kē)-中科(kē)院计算所数字眼科(kē)联合实验室”等创新(xīn)平台。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.
上市十年之际，爱尔眼科(kē)以“创新(xīn)驱动，科(kē)技爱尔”作為(wèi)指导方针，提出三大战略目标。第一个目标是要将爱尔眼科(kē)的医疗服務(wù)网络覆盖到广大城乡县域，让老百姓在家门口就能(néng)享受到高质量的、可(kě)及的眼科(kē)医疗服務(wù)，助推健康中國(guó)战略。第二个目标是希望通过打造世界级及國(guó)家级的眼科(kē)医學(xué)中心，切实提高中國(guó)眼科(kē)医疗技术水平，赶超世界先进水平。第三个目标是希望通过全球化布局，医、教、研、产、投全面协同发展，推动人类眼科(kē)學(xué)与视觉科(kē)學(xué)进步。
On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.
在十九年的创业发展历程中，爱尔眼科(kē)凝聚和培养了一批经验丰富、具有(yǒu)开拓创新(xīn)精神的管理(lǐ)团队和医术精良、治學(xué)严谨的眼科(kē)专家和医生团队。截至目前，爱尔眼科(kē)医院集团及旗下全球员工总数达50000余人，其中眼科(kē)医生及视光师总数(含海外) 9000余人，包括一大批博士生导师、硕士生导师、博士、博士后、留學(xué)欧美的學(xué)者以及临床经验丰富的核心专家。
Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.
爱尔眼科(kē)的发展壮大始终以“使所有(yǒu)人，无论贫穷富裕，都享有(yǒu)眼健康的权利”為(wèi)初心和使命，致力于全人类的光明事业，坚持“以患者為(wèi)中心”，追求社会责任和自身发展的和谐统一。通过开创性的“交叉补贴”模式，在為(wèi)患者提供更高品质的眼科(kē)医疗服務(wù)的同时，全面开展防盲治盲工作、投身社会公益、帮助弱势群體(tǐ)，积极联合社会各界力量，推动中國(guó)防盲事业乃至國(guó)民(mín)眼健康事业的全面发展。2018年、2020年蝉联第十届、第十一届中國(guó)政府荣誉慈善奖项“中华慈善奖”、荣获中國(guó)公益年会“中國(guó)公益企业奖”、“最佳社会责任上市公司”、“湖(hú)南慈善奖”等荣誉。同时积极响应國(guó)家号召，作為(wèi)中國(guó)代表企业牵头参与“一带一路光明行”、“湄公河光明行”等公益活动，获得组织者、受援國(guó)政府和患者的高度好评，逐步发展成為(wèi)全球慈善公益活动的一张名片。
The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.
爱尔眼科(kē)连续多(duō)年被专业机构评為(wèi)“中國(guó)最受投资者尊重的上市公司前十强”，蝉联中國(guó)品牌节“华谱奖”，荣获“最佳持续投资价值奖”、“中國(guó)上市公司最佳股东回报奖”、“中國(guó)上市公司实业贡献大奖”等多(duō)项殊荣，成功入选沪深300指数股、MSCI中國(guó)大盘指数成份股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
爱尔眼科(kē)医院集团是具有(yǒu)中國(guó)及全球范围医院规模和优质医疗能(néng)力的眼科(kē)医疗集团，服務(wù)覆盖亚洲、欧洲和北美洲，在中國(guó)内地、欧洲、东南亚拥有(yǒu)3家上市公司(中國(guó)A股：爱尔眼科(kē)，300015;西班牙：CBAV;新(xīn)加坡：40T)。目前在全球范围内开设眼科(kē)医院及中心达720家，其中中國(guó)内地611家、中國(guó)香港7家、美國(guó)1家、欧洲89家、东南亚12家。2020年，中國(guó)内地年门诊量超1000万人次，手术量超100万台，医疗服務(wù)网络覆盖全球近30亿人口。
AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.
爱尔眼科(kē)始终坚持以國(guó)内发展為(wèi)主線(xiàn)，國(guó)内國(guó)际双線(xiàn)并举，共同进步。在发展的过程中，致力于引进和吸收國(guó)际同步的眼科(kē)技术与医疗管理(lǐ)理(lǐ)念，以专业化、规模化、科(kē)學(xué)化為(wèi)发展战略，推动中國(guó)眼科(kē)医疗事业的发展。通过不断实践，在充分(fēn)吸收國(guó)际优质的医疗管理(lǐ)经验的基础上，成功探索出一套适应中國(guó)國(guó)情和市场环境的眼科(kē)医院连锁经营管理(lǐ)模式——“分(fēn)级连锁”，充分(fēn)发挥人才、技术和管理(lǐ)等方面的优势，提升诊疗质量、完善医疗服務(wù)、优化医患沟通。
Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.
AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.
科(kē)研创新(xīn)、人才培养是長(cháng)遠(yuǎn)发展的基石，爱尔眼科(kē)不断加大科(kē)研投入，大力支持开展前沿性、原创性的眼科(kē)學(xué)术研究，全力推进全球化平台上的眼健康生态圈战略。自2013年爱尔眼科(kē)与中南大學(xué)联合成立中南大學(xué)爱尔眼科(kē)學(xué)院，正式开启校企合作的创新(xīn)探索以来，陆续推动了与湖(hú)北科(kē)技學(xué)院、武汉大學(xué)、暨南大學(xué)、安徽医科(kē)大學(xué)、天津大學(xué)、四川大學(xué)等知名高校的战略合作，充分(fēn)发挥企业和高校的独特优势，在医院共建、人才培养、师资队伍建设、教學(xué)科(kē)研等领域展开深入合作，联手共建眼科(kē)医教研平台，合力打造“名校+名企”典范，為(wèi)社会培养更多(duō)优秀的眼科(kē)医學(xué)人才，真正地為(wèi)中國(guó)眼科(kē)學(xué)和视觉科(kē)學(xué)的创新(xīn)发展贡献智慧与力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.
在此基础上，爱尔眼科(kē)持续打造立體(tǐ)化科(kē)研平台，截止目前已在全國(guó)范围内构建起“八所、二站、二基地、三中心”的创新(xīn)型科(kē)教研一體(tǐ)化平台。“八所”：爱尔眼科(kē)研究所、爱尔眼视光研究所、爱尔角膜病研究所、爱尔屈光研究所、爱尔视网膜研究所、爱尔青光眼研究所、爱尔白内障与人工晶状體(tǐ)研究所、武汉爱尔眼科(kē)研究所。获批设立“二站”：國(guó)家博士后科(kē)研工作站、湖(hú)南省院士专家工作站；“二基地”：湖(hú)南省眼视光國(guó)际科(kē)技合作基地、湖(hú)南省“海智计划”工作基地；“三中心”：湖(hú)南省眼视光工程技术研究中心、湖(hú)南省眼表疾病临床医學(xué)研究中心、湖(hú)南省企业技术中心；联合共建“爱尔眼科(kē)-中科(kē)院计算所数字眼科(kē)联合实验室”等创新(xīn)平台。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.
上市十年之际，爱尔眼科(kē)以“创新(xīn)驱动，科(kē)技爱尔”作為(wèi)指导方针，提出三大战略目标。第一个目标是要将爱尔眼科(kē)的医疗服務(wù)网络覆盖到广大城乡县域，让老百姓在家门口就能(néng)享受到高质量的、可(kě)及的眼科(kē)医疗服務(wù)，助推健康中國(guó)战略。第二个目标是希望通过打造世界级及國(guó)家级的眼科(kē)医學(xué)中心，切实提高中國(guó)眼科(kē)医疗技术水平，赶超世界先进水平。第三个目标是希望通过全球化布局，医、教、研、产、投全面协同发展，推动人类眼科(kē)學(xué)与视觉科(kē)學(xué)进步。
On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.
在十九年的创业发展历程中，爱尔眼科(kē)凝聚和培养了一批经验丰富、具有(yǒu)开拓创新(xīn)精神的管理(lǐ)团队和医术精良、治學(xué)严谨的眼科(kē)专家和医生团队。截至目前，爱尔眼科(kē)医院集团及旗下全球员工总数达50000余人，其中眼科(kē)医生及视光师总数(含海外) 9000余人，包括一大批博士生导师、硕士生导师、博士、博士后、留學(xué)欧美的學(xué)者以及临床经验丰富的核心专家。
Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.
爱尔眼科(kē)的发展壮大始终以“使所有(yǒu)人，无论贫穷富裕，都享有(yǒu)眼健康的权利”為(wèi)初心和使命，致力于全人类的光明事业，坚持“以患者為(wèi)中心”，追求社会责任和自身发展的和谐统一。通过开创性的“交叉补贴”模式，在為(wèi)患者提供更高品质的眼科(kē)医疗服務(wù)的同时，全面开展防盲治盲工作、投身社会公益、帮助弱势群體(tǐ)，积极联合社会各界力量，推动中國(guó)防盲事业乃至國(guó)民(mín)眼健康事业的全面发展。2018年、2020年蝉联第十届、第十一届中國(guó)政府荣誉慈善奖项“中华慈善奖”、荣获中國(guó)公益年会“中國(guó)公益企业奖”、“最佳社会责任上市公司”、“湖(hú)南慈善奖”等荣誉。同时积极响应國(guó)家号召，作為(wèi)中國(guó)代表企业牵头参与“一带一路光明行”、“湄公河光明行”等公益活动，获得组织者、受援國(guó)政府和患者的高度好评，逐步发展成為(wèi)全球慈善公益活动的一张名片。
The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.
爱尔眼科(kē)连续多(duō)年被权威机构评為(wèi)“中國(guó)最受投资者尊重的上市公司前十强”，蝉联中國(guó)品牌节“华谱奖”，荣获“最佳持续投资价值奖”、“中國(guó)上市公司最佳股东回报奖”、“中國(guó)上市公司实业贡献大奖”等多(duō)项殊荣，成功入选沪深300指数股、MSCI中國(guó)大盘指数成份股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
